White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease
White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease
- # Parkinson's Disease With Dementia
- # Parkinson's Disease With Dementia Patients
- # Dementia With Lewy Bodies
- # Medial Temporal Lobe Atrophy
- # Alzheimer's Disease Patients
- # Medial Temporal Lobe Atrophy Score
- # Pathology In Dementia With Lewy Bodies
- # White Matter Hyperintensities
- # Alzheimer's Disease
- # Dementia With Lewy Bodies Patients
469
- 10.1161/01.str.19.10.1285
- Oct 1, 1988
- Stroke
49
- 10.1007/s00702-007-0856-8
- Feb 26, 2008
- Journal of Neural Transmission
76
- 10.1159/000107592
- Aug 24, 2007
- Dementia and Geriatric Cognitive Disorders
137
- 10.1016/j.neurobiolaging.2014.07.005
- Jul 15, 2014
- Neurobiology of Aging
206
- 10.1016/j.neurobiolaging.2004.10.006
- Dec 28, 2004
- Neurobiology of Aging
348
- 10.1007/s00401-017-1709-7
- Apr 11, 2017
- Acta Neuropathologica
365
- 10.1161/strokeaha.108.537704
- Dec 8, 2008
- Stroke
307
- 10.1136/jnnp.72.4.491
- Apr 1, 2002
- Journal of Neurology, Neurosurgery & Psychiatry
114
- 10.1371/journal.pone.0022506
- Jul 21, 2011
- PLoS ONE
76
- 10.1097/nen.0b013e3181d88e63
- May 1, 2010
- Journal of Neuropathology & Experimental Neurology
- Research Article
5
- 10.3389/fneur.2023.1203311
- Aug 9, 2023
- Frontiers in Neurology
Parkinson's disease (PD) is often accompanied by cognitive dysfunction, which imposes a heavy burden on patients, their families, and society. Early identification and intervention are particularly important, but reliable biomarkers for identifying PD-related cognitive impairment at an early stage are currently lacking. Although numerous clinical studies have investigated the association between brain white matter hyperintensity (WMH) and cognitive decline, the findings regarding the relationships between WMH and cognitive dysfunction in PD patients have been inconsistent. Therefore, this study aims to conduct a meta-analysis of the effect of WMH on PD cognitive function. This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines. We systematically searched relevant literature from databases such as PubMed, Web of Science, EMBASE, CNKI, and CBM. The retrieval time was limited to database records created up until December 31, 2022. Additionally, we manually retrieved references for full-text reading. Statistical data analysis was performed using RevMan 5.3 and Stata 15.0 software. This study encompassed 23 individual studies and involved 2,429 patients with PD. The group of PD with mild cognitive impairment (PD-MCI) exhibited a significantly higher overall level of WMH than the group of PD with normal cognitive function (PD-NC) (SMD = 0.37, 95% CI: 0.21-0.52, p < 0.01). This finding was consistent across subgroup analyses based on different ethnicities (Asian or Caucasian), WMH assessment methods (visual rating scale or volumetry), and age matching. In addition to the overall differences in WMH load between the PD-MCI and PD-NC groups, the study found that specific brain regions, including periventricular white matter hyperintensity (PVH) and deep white matter hyperintensity (DWMH), had significantly higher WMH load in the PD-MCI group compared to the PD-NC group. The study also conducted a meta-analysis of WMH load data for PD with dementia (PDD) and PD without dementia (PDND), revealing that the overall WMH load in the PDD group was significantly higher than that in the PDND group (SMD = 0.98, 95% CI: 0.56-1.41, p < 0.01). This finding was consistent across subgroup analyses based on different ethnicities and age matching. Moreover, regarding specific brain regions (PVH or DWMH), the study found that the PDD group had significantly higher WMH load than the PDND group (p < 0.01). WMH was associated with PD cognitive dysfunction. The early appearance of WMH may indicate PD with MCI.
- Supplementary Content
- 10.3390/ijms26167674
- Aug 8, 2025
- International Journal of Molecular Sciences
Dementia with Lewy bodies (DLB), the second common primary degenerative neurocognitive disorder after Alzheimer disease (AD), frequently presents concurrent co-pathologies that impact clinical presentation and progression. Neuropathological studies have demonstrated a high prevalence of coexistent AD-related neuropathological changes (ADNC), TAR DNA-binding protein 43 (TDP-43) proteinopathies, and cardiac and aging-related disorders, while frontotemporal lobar degeneration (FTLD) and tau-related syndromes play a minor role as DLB-related co-pathologies. Cerebrovascular lesions, including cerebral amyloid angiopathy, are the most prevalent non-neurodegenerative co-pathologies. Cardiovascular disorders, hypertension, and hyperlipidemia are also frequent comorbidities. Due to their high prevalence and clinical impact on DLB patients, clinical trials should account for these and other co-pathologies in their design and selection. Evaluation of these co-pathologies using and interpreting biomarkers may allow greater clinical diagnostic accuracy and the opportunity to better predict clinical progression. Therefore, there is an increasing need for biomarkers in dementia research. This review discusses the kind and frequency of the different co-pathologies in DLB and their clinical impact. It evaluates the possible value of disease-specific biomarkers and how they are helpful in the assessment and prevention of DLB and its co-pathologies.
- Research Article
35
- 10.1007/s00702-019-02028-6
- Jun 18, 2019
- Journal of Neural Transmission
Extrapyramidal movement disorders include hypokinetic rigid and hyperkinetic or mixed forms, most of them originating from dysfunction of the basal ganglia (BG) and their information circuits. The functional anatomy of the BG, the cortico-BG-thalamocortical, and BG-cerebellar circuit connections are briefly reviewed. Pathophysiologic classification of extrapyramidal movement disorder mechanisms distinguish (1) parkinsonian syndromes, (2) chorea and related syndromes, (3) dystonias, (4) myoclonic syndromes, (5) ballism, (6) tics, and (7) tremor syndromes. Recent genetic and molecular-biologic classifications distinguish (1) synucleinopathies (Parkinson's disease, dementia with Lewy bodies, Parkinson's disease-dementia, and multiple system atrophy); (2) tauopathies (progressive supranuclear palsy, corticobasal degeneration, FTLD-17; Guamian Parkinson-dementia; Pick's disease, and others); (3) polyglutamine disorders (Huntington's disease and related disorders); (4) pantothenate kinase-associated neurodegeneration; (5) Wilson's disease; and (6) other hereditary neurodegenerations without hitherto detected genetic or specific markers. The diversity of phenotypes is related to the deposition of pathologic proteins in distinct cell populations, causing neurodegeneration due to genetic and environmental factors, but there is frequent overlap between various disorders. Their etiopathogenesis is still poorly understood, but is suggested to result from an interaction between genetic and environmental factors. Multiple etiologies and noxious factors (protein mishandling, mitochondrial dysfunction, oxidative stress, excitotoxicity, energy failure, and chronic neuroinflammation) are more likely than a single factor. Current clinical consensus criteria have increased the diagnostic accuracy of most neurodegenerative movement disorders, but for their definite diagnosis, histopathological confirmation is required. We present a timely overview of the neuropathology and pathogenesis of the major extrapyramidal movement disorders in two parts, the first one dedicated to hypokinetic-rigid forms and the second to hyperkinetic disorders.
- Research Article
16
- 10.1212/wnl.0000000000201579
- Nov 28, 2022
- Neurology
Although alpha-synuclein-related pathology is the hallmark of dementia with Lewy bodies (DLB), cerebrovascular and Alzheimer disease pathologies are common in patients with DLB. Little is known about the contribution of these pathologies to neurodegeneration in DLB. We investigated associations of cerebrovascular, β-amyloid, and tau biomarkers with gray matter (GM) volume in patients with probable DLB. We assessed patients with probable DLB and cognitively unimpaired (CU) controls with 11C-Pittsburgh compound B (PiB) and 18F-flortaucipir PET as markers of β-amyloid and tau, respectively. MRI was used to assess white matter hyperintensity (WMH) volume (a marker of cerebrovascular lesion load) and regional GM volume (a marker of neurodegeneration). We used correlations and analysis of covariance (ANCOVA) in the entire cohort and structural equation models (SEMs) in patients with DLB to investigate associations of WMH volume and regional β-amyloid and tau PET standardized uptake value ratios (SUVrs) with regional GM volume. We included 30 patients with DLB (69.3 ± 10.2 years, 87% men) and 100 CU controls balanced on age and sex. Compared with CU controls, patients with DLB showed a lower GM volume across all cortical and subcortical regions except for the cuneus, putamen, and pallidum. A larger WMH volume was associated with a lower volume in the medial and orbital frontal cortices, insula, fusiform cortex, and thalamus in patients with DLB. A higher PiB SUVr was associated with a lower volume in the inferior temporal cortex, while flortaucipir SUVr did not correlate with GM volume. SEMs showed that a higher age and absence of the APOE ε4 allele were significant predictors of higher WMH volume, and WMH volume in turn was a significant predictor of GM volume in medial and orbital frontal cortices, insula, and inferior temporal cortex. By contrast, we observed 2 distinct paths for the fusiform cortex, with age having an effect through PiB and flortaucipir SUVr on one path and through WMH volume on the other path. Patients with probable DLB have widespread cortical atrophy, most of which is likely influenced by alpha-synuclein-related pathology. Although cerebrovascular, β-amyloid, and tau pathologies often coexist in probable DLB, their contributions to neurodegeneration seem to be region specific.
- Research Article
- 10.3389/fradi.2025.1554345
- Apr 4, 2025
- Frontiers in Radiology
Background and aimLewy body diseases (LBD) include neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD). Because DLB and Alzheimer's disease (AD) share similar neurological symptoms, DLB is frequently underdiagnosed. White Matter Hyperintensities (WMH) are associated with dementia risk and changes in both DLB and AD. In order to examine WMH discrepancies in DLB and AD patients and gain insight into their diagnostic utility and pathophysiological significance, this systematic review and meta-analysis is conducted.Material and methodsDatabases such as PubMed, Scopus, Google Scholar, and Web of Science were searched for studies reporting WMH in DLB and AD patients based on Preferred Reporting Items for Systematic Review (PRISMA) guideline. Stata version 15 US is used to analyze the extracted data.ResultsTwelve studies with 906 AD and 499 DLB patients were considered in this analysis. Although not statistically significant, the WMH was 0.03 ml larger in AD patients than in DLB patients. The prevalence of hypertension varied, ranging from 21% to 56% in DLB patients and from 30% to 52% in AD patients. Different findings were found on the prevalence of diabetes; some research suggested that DLB patients had greater rates (18.7%–37%) than AD patients (9%–17.5%). The imaging modalities FLAIR, T2-weighted, and T1-weighted sequences were employed. Compared to DLB patients, AD patients had higher cortical and infratentorial infarcts.ConclusionThose with AD have greater WMH volumes than cases with DLB, suggesting that WMH can be a biomarker to help better differentiation between these neurodegenerative diseases; however, this difference is not significant. To better understand the therapeutic implications and options for reducing WMH-related cognitive loss in various patient populations, more research is necessary.
- Research Article
- 10.1007/s00415-024-12662-0
- Sep 2, 2024
- Journal of Neurology
White matter hyperintensities (WMH) are considered magnetic brain imaging (MRI) biomarkers of cerebral small vessel disease but their clinical role in neurodegenerative-related disorders is poorly understood. This study describes the distribution of WMH on brain MRI in Progressive Supranuclear Palsy (PSP) in comparison with Parkinson’s disease (PD) and explores their possible impact on disease’s features. Sixty PSP and 33 PD patients were included. Motor symptoms, cardiovascular risk factors and the age-related white matter changes (ARWMC) score was computed to rate WMH for both groups. Pearson’s correlation and linear or logistic regression analysis were used to check for relationships between ARWMC and PSP clinical scores. The mean (standard deviation) ARWMC total score in the PSP cohort was 4.66 (3.25). Any degree of WMH was present in 68% of PSP (ARWMC +). Compared to ARWMC-, ARWMC + did not have greater disease severity or more cardiovascular risk factors. WMH were frequently localized in fronto-parietal lobes and were mild in severity. Linear regression analysis showed that ARWMC total score was related to the PSP-rating scale, irrespective of age, disease duration and the Charlson modified comorbidity index. Logistic regression analysis confirmed that ARWMC total score was related to the use of wheelchair, irrespective of above-mentioned covariates. Vascular risk factors as well as severity and distribution of WMH did not have an impact on the PSP phenotype. No differences were found with PD patients. Our results suggest that WMH in PSP might be markers of neurodegenerative-related pathology rather than being simple expression of atherosclerotic cerebrovascular changes.
- Research Article
6
- 10.3389/fneur.2021.733570
- Nov 5, 2021
- Frontiers in Neurology
Dementia and mild forms of cognitive impairment as well as neuropsychiatric symptoms (i. e., impulse control disorders) are frequent and disabling non-motor symptoms of Parkinson's disease (PD). The identification of changes in neuroimaging studies for the early diagnosis and monitoring of the cognitive and neuropsychiatric symptoms associated with Parkinson's disease, as well as their pathophysiological understanding, are critical for the development of an optimal therapeutic approach. In the current literature review, we present an update on the latest structural and functional neuroimaging findings, including high magnetic field resonance and radionuclide imaging, assessing cognitive dysfunction and impulse control disorders in PD.
- Research Article
12
- 10.21037/qims-20-1355
- Sep 1, 2021
- Quantitative Imaging in Medicine and Surgery
This study sought to validate the clinical utility of multimodal magnetic resonance imaging (MRI) techniques in the assessment of neurodegenerative disorders. We intended to demonstrate that advanced neuroimaging techniques commonly used in research can effectively be employed in clinical practice to accurately differentiate heathy aging and dementia subtypes. Twenty patients with dementia of the Alzheimer's type (DAT) and 18 patients with Parkinson's disease dementia (PDD) were identified using gold-standard techniques. Twenty-three healthy, age and sex matched control participants were also recruited. All participants underwent multimodal MRI including T1 structural, diffusion tensor imaging (DTI), arterial spin labeling (ASL), and magnetic resonance spectroscopy (MRS). MRI modalities were evaluated by trained neuroimaging readers and were separately assessed using cross-validated, iterative discriminant function analyses with subsequent feature reduction techniques. In this way, each modality was evaluated for its ability to differentiate patients with dementia from healthy controls as well as to differentiate dementia subtypes. Following individual and group feature reduction, each of the multimodal MRI metrics except MRS successfully differentiated healthy aging from dementia and also demonstrated distinct dementia subtypes. Using the following ten metrics, excellent separation (95.5% accuracy, 92.3% sensitivity; 100.0% specificity) was achieved between healthy aging and neurodegenerative conditions: volume of the left frontal pole, left occipital pole, right posterior superior temporal gyrus, left posterior cingulate gyrus, right planum temporale; perfusion of the left hippocampus and left occipital lobe; fractional anisotropy (FA) of the forceps major and bilateral anterior thalamic radiation. Using volume of the left frontal pole, right posterior superior temporal gyrus, left posterior cingulate gyrus, perfusion of the left hippocampus and left occipital lobe; FA of the forceps major and bilateral anterior thalamic radiation, neurodegenerative subtypes were accurately differentiated as well (87.8% accuracy, 95.2% sensitivity; 85.0% specificity). Regional volumetrics, DTI metrics, and ASL successfully differentiated dementia patients from controls with sufficient sensitivity to differentiate dementia subtypes. Similarly, feature reduction results suggest that advanced analyses can meaningfully identify brain regions with the most positive predictive value and discriminant validity. Together, these advanced neuroimaging techniques can contribute significantly to diagnosis and treatment planning for individual patients.
- Research Article
9
- 10.1016/j.parkreldis.2021.09.025
- Sep 30, 2021
- Parkinsonism & Related Disorders
A multiparametric MRI study of structural brain damage in dementia with lewy bodies: A comparison with Alzheimer's disease
- Research Article
13
- 10.1016/j.parkreldis.2020.07.025
- Aug 10, 2020
- Parkinsonism & Related Disorders
Diffusion imaging in dementia with Lewy bodies: Associations with amyloid burden, atrophy, vascular factors and clinical features
- Research Article
60
- 10.1002/mds.22919
- Jan 30, 2010
- Movement Disorders
Visual hallucinations (VHs) are common in dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD), while auditory hallucinations are rare. To neurophysiologically investigate the pathophysiology of VHs in these disorders, we studied event-related potentials (ERPs) of DLB, PDD, and Alzheimer's disease (AD) patients. We compared visual and auditory ERP latencies among PDD patients with and without VHs (PDD-H: 11, PDD-N: 6), DLB patients (24), and AD patients (21). To elicit visual and auditory ERPs, a facial discrimination paradigm and a conventional auditory odd-ball paradigm, respectively, were used. The mean visual P3 latencies in the PDD-H and DLB groups were significantly longer than that in the AD group, while the mean auditory P3 latencies in all four patient groups were comparable. The mean visual P2 latencies in the PDD-N, PDD-H, and DLB groups were significantly longer than that in the control group. Our findings suggest that visual cognitive functions are selectively impaired in hallucinatory patients with DLB and PDD. VHs may be associated in part with predominant visual cognitive impairments attributable to PDD and DLB pathologies. Our findings also suggest that the impairments occur at the early stage of facial information processing.
- Research Article
87
- 10.1007/s00415-005-0023-9
- Nov 4, 2005
- Journal of Neurology
To study the use of transcranial sonography (TCS) in discriminating between patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). Fourteen patients with DLB, 31 with PDD and 73 with PD without dementia (PDnD) were studied with TCS. All assessable patients with DLB, 97% with PDD, and 94% with PDnD showed at least unilateral hyperechogenicity of substantia nigra (SN). However, bilateral marked SN hyperechogenicity was present in 80% of DLB patients but only in one third of PDD and PDnD patients, and was associated with younger age at disease onset in PD but not in DLB. An asymmetry index > or = 1.15 of bilateral SN echogenic sizes, estimated by division of larger size by smaller size, was found in 69% of PDD patients but only 20% of DLB patients. Combination of SN echogenic sizes, asymmetry indices and onset age discriminated PDD from DLB with a sensitivity of 96%, a specificity of 80% and a positive predictive value of 93%. TCS of brainstem raphe, thalami, lenticular nuclei, caudate nuclei and ventricle widths did not discriminate between DLB and PDD. Compared with PDnD patients, DLB and PDD patients exhibited significantly larger widths of third ventricle and of frontal horns. In PDD patients, scores on the Unified Parkinson's Disease Rating Scale correlated with widths of third ventricle and of frontal horns. SN hyperechogenicity is typical for PDD and DLB. However, size, asymmetry and relation of SN hyperechogenicity to age at disease onset discriminate PDD from DLB.
- Research Article
253
- 10.1002/mds.10633
- Jan 1, 2004
- Movement Disorders
We compared the clinical and neuropsychological pattern of dementia with Lewy bodies (DLB) to Alzheimer's disease (AD) and Parkinson's disease with dementia (PD-d). Sixteen patients clinically diagnosed with DLB were compared with two groups of patients with PD-d (n = 15) and AD (n = 16) matched for level of dementia. Isolated cognitive impairment was the most common form of presentation in AD (93.8%) and DLB (31.3%) groups, while parkinsonism was in 100% of PD-d subjects. Psychoses associated with cognitive impairment at the beginning of the disease were more frequent in DLB patients (31.3%) than in AD (6.3%) and PD-d (0%) groups. There were no significant differences in Unified Parkinson Disease Rating Scale motor-subscale scores between DLB and PD-d patients. DLB and PD-d patients performed significantly worse on attentional functions and better on memory tests than AD. DLB patients also showed lower scores than AD subjects on visual memory, visuoperceptive, and visuoconstructive tests. No significant differences were found between PD-d group and DLB subjects on any neuropsychological test. We were unable to find any differences in cognitive tasks between PD-d and DLB subjects. Clinical features and neuropsychological deficiencies of DLB (attentional, visuoperceptive, and visuoconstructive deficits) and PD (attentional deficits) compared to AD (amnesic syndrome) can contribute to accurate identification of these entities and to the understanding of the neuropathological and neurochemical substrate underlying these diseases.
- Research Article
4
- 10.1016/j.ahr.2022.100096
- Aug 30, 2022
- Aging and Health Research
Gender differences in Parkinson's disease with dementia and dementia with Lewy bodies
- Research Article
340
- 10.1093/brain/awm322
- Feb 7, 2008
- Brain
EEG abnormalities have been reported for both dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Although it has been suggested that variations in mean EEG frequency are greater in the former, the existence of meaningful differences remains controversial. No evidence is as yet available for Parkinson's disease with dementia (PDD). The aim of this study was to evaluate whether EEG abnormalities can discriminate between DLB, AD and PDD in the earliest stages of dementia and to do this 50 DLB, 50 AD and 40 PDD patients with slight cognitive impairment at first visit (MMSE > or = 20) were studied. To improve clinical diagnostic accuracy, special emphasis was placed on identifying cognitive fluctuations and REM-sleep behaviour disorder. EEG variability was assessed by mean frequency analysis and compressed spectral arrays (CSA) in order to detect changes over time from different scalp derivations. Patients' initial diagnoses were revised at a 2-year follow-up visit with neuroimaging evaluation. Initial diagnoses were confirmed in 36 DLB, 40 AD and 35 PDD patients. The most relevant group differences were observed between the AD and DLB patients in EEGs from posterior derivations (P<0.001). Dominant frequencies were 8.3 +/- 0.6 Hz for the AD group and 7.4 +/- 1.6 Hz for the DLB group, in which most of the patients (88%) exhibited a frequency band of 5.6-7.9 Hz. Dominant frequency variability also differed between the AD (1.1 +/- 0.4 Hz) and DLB groups (1.8 +/- 1.2 Hz, P<0.001). Of note, less than a half (46%) of the patients with PDD exhibited the EEG abnormalities seen in those with DLB. Graded according to the presence of alpha activity, five different patterns were identified on EEG CSA from posterior derivations. A pattern with dominant alpha bands was observed in patients with AD alone while, in those with DLB and PDD, the degree to which residual alpha and 5.6-7.9 bands appeared was related to the presence and severity of cognitive fluctuations. At follow-up, EEG abnormalities from posterior leads were seen in all subjects with DLB and in three-quarters of those with PDD. Of interest, in four patients initially labelled as having AD, in whom the occurrence of fluctuations and/or REM-sleep behaviour disorder during the 2-year follow-up had made the diagnosis of AD questionable, the initial EEG was characterized by the features observed in the DLB group. If revised consensus criteria for DLB diagnosis are properly applied (i.e. emphasizing the diagnostic weight of fluctuations and REM sleep behaviour disorder), EEG recording may act to support discrimination between AD and DLB at the earliest stages of dementia, since characteristic abnormalities may even precede the appearance of distinctive clinical features.
- Research Article
- 10.3760/cma.j.issn.1007-1245.2018.19.035
- Oct 1, 2018
Objective To investigate the clinical features in patients with Parkinson disease with dementia (PDD) and dementia with lewy bodies (DLB), in order to provide evidence for clinical diagnosis. Methods 36 patients with DLB and 24 patients with PDD were collected in department of neurology of our hospital from March 2015 to December 2017. The severity of motor symptoms, cognitive function, and mental behavior symptoms were compared between the two groups. Results The course of disease in DLB group was significantly shorter than that in PDD group [(2.13±1.98)d vs.(5.65±3.59)d]. The scores of UPDRSⅢ and tremor in DLB group were lower than those in PDD group [(26.73±11.61) vs.(37.16±13.73), (2.59±1.83) vs.(5.15±3.59)], but the score of posture and gait disorder in DLB group was higher than that in PDD group [(9.16±1.64) vs.(6.35±2.48)] (P<0.05). The scores of MMSE, MoCA, and CDT in DLB group were lower than those in PDD group (P<0.05). The rates of illusion and emotional instability in DLB group were higher than those in PDD group, the rates of apathy, depression, anxiety, and sleep disorders in DLB group were lower than those in PDD group (P<0.05). Conclusion Cognitive impairment is more progressive in DLB patients compared with PDD patients. Hallucinations and emotional instability are more common in DLB patients, but depression, anxiety, and sleep disorders are more common in PDD patients. Key words: Dementia with lewy bodies; Parkinson disease with dementia; Clinical features
- Research Article
164
- 10.1016/j.biopsych.2008.02.016
- Apr 8, 2008
- Biological Psychiatry
Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
- Research Article
45
- 10.1007/s00415-010-5453-3
- Jan 22, 2010
- Journal of Neurology
To examine the occurrence of fluctuating cognition (FC) in a group of patients with Parkinson's disease with dementia (PDD), and to determine whether the presence of FC in PDD is associated with a pattern of cognitive and behavioural disturbances similar to the one shown by patients affected by dementia with Lewy bodies (DLB), a cluster analysis was carried out on the scores obtained by 27 PDD patients on the Clinician Assessment of Fluctuation Scale (CAF). The analysis separated the PDD patients into two subgroups, called PDD non-fluctuators (PDDNF; CAF <or= 2) and PDD fluctuators (PDDF; CAF > 2). The two groups underwent a cognitive and behavioural evaluation. Their scores were compared with those obtained by DLB and Alzheimer's disease (AD) patients. When exploring the cognitive performance of the patients with the Dementia Rating Scale-2 (DRS-2), PDDF had a similar pattern of impairments compared to DLB, which involved prevalently the attention and initiation/perseveration domains, and which was significantly more pronounced compared to that shown by PDDNF. The main behavioural finding of the study was the similar incidence of visual hallucinations in the PDDF and DLB groups, which was significantly higher compared to PDDNF and AD. Our results confirmed the hypothesis that subgroups with different cognitive profiles exist within PDD and that the occurrence of FC is the clinical variable associated with a DLB pattern of impairment in PDD. In conclusion, our study suggests that when FC occurs in PDD this syndrome becomes clinically undistinguishable from DLB.
- Research Article
2
- 10.1016/j.pin.2015.02.002
- Jan 1, 2015
- Postępy Psychiatrii i Neurologii
Background The study is aimed at assessing the usefulness of 99m Tc-ECD SPECT in distinguishing patients with: Dementia with Lewy Bodies (DLB), Alzheimer's disease (AD) and Parkinson's disease with dementia (PD-D). Methods Fifty patients participated in the study: 13 patients with DLB (aged 74 ± 4 years), 19 patients with AD (aged 75 ± 7 years), 18 patients with PD-D (aged 72 ± 3 years) and 14 healthy individuals (aged 70 ± 6 years). A neuropsychological examination was conducted on all patients. Motor function of DLB and PD-D patients was assessed using the Hoehn-Yahr scale, Unified Parkinson's Disease Rating Scale and Schwab and England Activities of Daily Living Scale. 99m Tc-ECD SPECT was performed on all subjects. Statistical analysis of radiotracer uptake was performed for 16 regions of interest. To differentiate patients with DLB, PD-D and AD discriminate analysis was conducted. Results SPECT showed global hypoperfusion in all patient groups when compared to control group. In DLB perfusion was significantly lower within the left temporal region as compared to AD and within the right parietal region, left temporo-occipital junction and left thalamus as compared to PD-D. A significant decrease of perfusion in both thalami was found in PD-D in comparison to AD. Discriminate analysis allowed for the proper classification in 68% of all patients: PD-D was classified the most accurately (83%) and DLB with least precision (46%). Conclusions 99m Tc-ECD SPECT did not allow us to differentiate precisely among DLB, PD-D and AD. Overlapping neuropathological features of DLB, PD-D and AD may account for this pattern of perfusion.
- Research Article
184
- 10.1186/alzrt255
- Jan 1, 2014
- Alzheimer's Research & Therapy
IntroductionThe objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD), compared with age-matched controls.MethodsIn total, 247 CSF samples were assessed in this study, including 71 patients with DLB, 30 patients with PDD, 48 patients with AD, and 98 healthy age-matched controls. Both total and oligomeric α-synuclein levels were evaluated by using well-established immunoassays.ResultsThe levels of α-synuclein oligomers in the CSF were increased in patients with PDD compared with the controls (P < 0.05), but not in patients with DLB compared with controls. Interestingly, the levels of α-synuclein oligomers in the CSF were also significantly higher in patients with PDD (P < 0.01) and DLB (P < 0.05) compared with patients with AD. The levels of CSF α-synuclein oligomers and the ratio of oligomeric/total-α-synuclein could distinguish DLB or PDD patients from AD patients, with areas under the curves (AUCs) of 0.64 and 0.75, respectively. In addition, total-α-synuclein alone could distinguish DLB or PDD patients from AD patients, with an AUC of 0.80.ConclusionsThe levels of α-synuclein oligomers were increased in the CSF from α-synucleinopathy patients with dementia compared with AD cases.
- Research Article
75
- 10.1016/j.parkreldis.2015.06.013
- Jun 16, 2015
- Parkinsonism & Related Disorders
Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia.
- Research Article
124
- 10.1093/jnen/nlw070
- Aug 11, 2016
- Journal of Neuropathology & Experimental Neurology
Parkinson disease (PD), Parkinson disease with dementia (PDD), and Dementia with Lewy bodies (DLB) differ clinically with regard to the presence and timing of dementia. In this postmortem study, we evaluated whether the burden and distribution pattern of amyloid-β (Aβ) pathology differs among these disease entities. We assessed Aβ phases and neuritic plaque scores in 133 patients fulfilling clinical diagnostic criteria for PD, PDD, and DLB, and determined the presence and load of Aβ pathology in 5 cortical and 4 subcortical regions in a subset of patients (n = 89) using a multispectral imaging system. Aβ phases and neuritic plaque scores were higher in DLB versus PDD (both p < 0.001) and in PDD vs PD patients (p = 0.020 and 0.022, respectively). Aβ pathology was more often observed in the entorhinal cortex, amygdala and putamen in DLB versus PDD patients; Aβ load was higher in both cortical and subcortical regions. PDD patients had more frequent Aβ pathology in temporal cortex and higher Aβ load in cortical regions and striatum versus PD patients. Our findings suggest that the load and extent of Aβ pathology may contribute to cognitive dysfunction in PDD and the early-stage severe dementia in DLB.
- Research Article
15
- 10.1159/000484409
- Nov 13, 2017
- European Neurology
Objective: We studied autonomic disturbance in patients with dementia with Lewy bodies (DLB), Parkinson disease with dementia (PDD), Alzheimer disease (AD), to determine whether autonomic function tests can be used to distinguish these disorders. Methods: Autonomic function was tested in 56 patients with DLB, 37 patients with PDD, and 59 patients with AD by using the sympathetic skin response, coefficient of variation in R-R interval, the head-up tilt test, serum norepinephrine concentration, and 123I-meta-iodobenzylguanidine cardiac scintigraphy. Symptoms of autonomic dysfunction, such as constipation, urinary symptoms, and orthostatic hypotension, were also noted. Results: The groups did not differ on baseline characteristics other than those associated with Parkinsonism and dementia. All patients with DLB and PDD had some dysautonomia, whereas rates were much lower for patients with AD (19%). Significantly more DLB and PDD patients than AD patients showed abnormalities on autonomic function tests. Conclusions: Autonomic function tests might be quite useful to distinguish DLB and PDD from AD.
- Research Article
39
- 10.2147/ndt.s45840
- Jan 1, 2013
- Neuropsychiatric Disease and Treatment
IntroductionWhether dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) should be considered as one entity or two distinct conditions is a matter of controversy. The aim of this study was to compare the characteristics of DLB and PDD patients using data from the Swedish Dementia Quality Registry (SveDem).MethodsSveDem is a national Web-based quality registry initiated to improve the quality of diagnostic workup, treatment, and care of patients with dementia across Sweden. Patients with newly diagnosed dementia of various types were registered in SveDem during the years 2007–2011. The current cross-sectional report is based on DLB (n = 487) and PDD (n = 297) patients. Demographic characteristics, diagnostic workup, Mini-Mental State Examination (MMSE) score, and medications were compared between DLB and PDD groups.ResultsNo gender differences were observed between the two study groups (P = 0.706). PDD patients were significantly younger than DLB patients at the time of diagnosis (74.8 versus 76.8 years, respectively; P < 0.001). A significantly higher prevalence of patients with MMSE score ≤24 were found in the PDD group (75.2% versus 67.6%; P = 0.030). The mean number of performed diagnostic modalities was significantly higher in the DLB group (4.9 ± 1.7) than in the PDD group (4.1 ± 1.6; P < 0.001). DLB patients were more likely than PDD patients to be treated with cholinesterase inhibitors (odds ratio = 2.5, 95% confidence interval = 1.8–3.5), whereas the use of memantine, antidepressants, and antipsychotics did not differ between the groups.ConclusionThis study demonstrates several differences in the dementia work-up between DLB and PDD. The onset of dementia was significantly earlier in PDD, while treatment with cholinesterase inhibitors was more common in DLB patients. Severe cognitive impairment (MMSE score ≤24) was more frequent in the PDD group, whereas more diagnostic tests were used to confirm a DLB diagnosis. Some similarities also were found, such as gender distribution and use of memantine, antidepressants, and antipsychotics drugs. Further follow-up cost-effectiveness studies are needed to provide more evidence for workup and treatment guidelines of DLB and PDD.
- Research Article
27
- 10.1080/13803390802572401
- Sep 10, 2009
- Journal of Clinical and Experimental Neuropsychology
This study compared verbal learning and memory in patients with autopsy-confirmed dementia with Lewy bodies (DLB) and patients with Parkinson's disease with dementia (PDD). A total of 24 DLB patients, 24 PDD patients, and 24 normal comparison participants were administered the California Verbal Learning Test. The three groups were matched on demographic variables, and the two patient groups were matched on the Mattis Dementia Rating Scale. The results indicated that DLB patients recalled less information than PDD patients on all but one recall measure and displayed a more rapid rate of forgetting. In contrast, the PDD patients committed a greater percentage of perseveration errors than the DLB patients. The two groups did not differ in the percentage of recall intrusion errors or any measures of recognition. A discriminant function analysis (DFA) using short-delay cued recall, percentage of perseveration errors, and List B recall differentiated the DLB and PDD groups with 81.3% accuracy. The application of the DFA algorithm to another sample of 42 PDD patients resulted in a 78.6% correct classification rate. The results suggest that, despite equivalent levels of general cognitive impairment, patients with DLB or PDD exhibit a different pattern of verbal learning and memory deficits.
- Research Article
- 10.1016/j.jns.2025.123747
- Nov 1, 2025
- Journal of the Neurological Sciences
- Research Article
- 10.1016/j.jns.2025.123746
- Nov 1, 2025
- Journal of the Neurological Sciences
- Research Article
- 10.1016/j.jns.2025.123723
- Nov 1, 2025
- Journal of the neurological sciences
- Discussion
- 10.1016/j.jns.2025.123719
- Nov 1, 2025
- Journal of the neurological sciences
- Discussion
- 10.1016/j.jns.2025.123729
- Nov 1, 2025
- Journal of the neurological sciences
- Research Article
- 10.1016/j.jns.2025.123722
- Nov 1, 2025
- Journal of the neurological sciences
- Discussion
- 10.1016/j.jns.2025.123675
- Nov 1, 2025
- Journal of the neurological sciences
- Research Article
- 10.1016/j.jns.2025.123708
- Nov 1, 2025
- Journal of the neurological sciences
- Research Article
- 10.1016/j.jns.2025.123744
- Nov 1, 2025
- Journal of the Neurological Sciences
- Discussion
- 10.1016/j.jns.2025.123713
- Nov 1, 2025
- Journal of the neurological sciences
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.